Clinical trials: Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease, COPD
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.
- Trial name
- NCT00496470
- Testing
- Symbicort (budesonide/formoterol turbuhaler 320/9ug), Spiriva (tiotropium bromide 18ug)
- Where
- 93 sites in Australia, Canada and 7 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Graft Versus Host Disease
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
- Trial name
- NCT02195869
- Testing
- Ibrutinib
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pharmacyclics LLC.
Cachexia
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
Impaired physical function and muscle dysfunction are a major consequence of COPD, which may be associated with increased mortality, poor quality of life and increased health care use.
- Trial name
- NCT03359473
- Testing
- GSK2881078
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment…
- Trial name
- NCT05878769
- Testing
- Astegolimab
- Where
- 481 sites in United States, Argentina and 38 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Emphysema, Pulmonary Disease, Chronic Obstructive
A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema
The Pulmair Implantable Artificial Bronchus (IAB) is a device intended for implantation into the diseased bronchi of emphysema patients.
- Trial name
- IAB-1 (NCT05087641)
- Testing
- IAB System
- Where
- 3 sites in Brazil, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- Pulmair Medical, Inc.
Chronic Obstructive Pulmonary Disease
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of…
- Trial name
- NCT00206154
- Testing
- Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
- Where
- 212 sites in United States, Czechia and 3 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to tiotropium 10 μg, formulated as inhalation powder in the polyethylene hard capsule and delivered via the HandiHaler® 2, compared to…
- Trial name
- NCT02242266
- Testing
- Tiotropium low dose, Tiotropium medium dose, Spiriva® HandiHaler® high dose
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
Reports suggest that the Medicaid population includes a higher percentage of smokers than the general population. A high prevalence of smokers in a population is likely to lead to a higher burden of chronic obstructive pulmonary…
- Trial name
- NCT01615783
- Testing
- Subjects with COPD, Subjects without COPD
- Volunteers
- 40,884 people
- Sponsor
- GlaxoSmithKline
COPD
Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute
This is an eight-week, randomized, controlled, two arm parallel study. The study consists of, a screening visit, two weeks of intervention-free run-in randomization, clinic visits week 0, 1, 2, 4, 6, and 8 weeks during the…
- Trial name
- NCT00560105
- Testing
- Lung Flute, Acapella
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical Acoustics LLC
COPD (Chronic Obstructive Pulmonary Disease)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated…
- Trial name
- THARROS (NCT06283966)
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
- Where
- 922 sites in United States, Argentina and 35 more
- Volunteers
- 5,250 people
- Sponsor
- AstraZeneca
Respiratory Disorders
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence…
- Trial name
- NCT03151395
- Testing
- Sputum and blood sampling
- Where
- 19 sites in Hong Kong, Philippines and 2 more
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07108699
- Testing
- HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler Simulant
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Pulmonary Obstructive Disease, Emphysema
A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long term safety and efficacy information about the AeriSeal System treatment in patients with advanced emphysema.
- Trial name
- NCT01449175
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 54 people
- Sponsor
- Aeris Therapeutics
Asthma
MK0524 Asthma POC Study (0524-008)(COMPLETED)
The purpose of the study is to demonstrate the benefit of MK0524 compared to placebo in patients with chronic asthma.
- Trial name
- NCT00783601
- Testing
- Comparator: MK0524 + montelukast
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects…
- Trial name
- NCT01777334
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 70 sites in United States, Argentina and 7 more
- Volunteers
- 905 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Lung Disease (COLD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07140328
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID, HSK39004 Dry Powder Inhaler -1.5mg BID, HSK39004 Inhalation Suspension -3mg BID
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events…
- Trial name
- NCT02077465
- Testing
- Andecaliximab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Gilead Sciences
COPD (Chronic Obstructive Pulmonary Disease)
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD
This clinical trial evaluates the long-term safety and efficacy of 3 mg HSK39004 Inhalation Suspension administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive…
- Trial name
- NCT07634367
- Testing
- HSK39004 Inhalation Suspension
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
Primary Objective: To evaluate the pharmacokinetics of Tiotropium Bromide Inhalation Powder (Strength:18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co.
- Trial name
- NCT06326671
- Testing
- Tiotropium Bromide Inhalation Powder, Spiriva HandiHaler
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00215436
- Testing
- Formoterol Fumarate
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.